I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

Leicester is the weight loss injection capital with almost 2,000 drugs prescribed each month, 6.8 times the proportion dished ...

First Amendment: Congress shall make no law respecting an establishment of religion, or prohibiting the free exercise thereof; or abridging the freedom of speech, or of the press; or the right of the ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic ...

Wave received supportive initial feedback from FDA, who recognize the severity of HD and are receptive to and engaged with Wave regarding a potential pathway to accelerated approval. FDA is open to ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Some people are microdosing certain weight loss drugs in an attempt to reap some of the drugs' benefits with fewer of their side effects. But doctors specializing in weight loss say that ...

Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. | ...